CA2150550A1
(en)
|
1992-12-01 |
1994-06-09 |
Melissa S. Egbertson |
Fibrinogen receptor antagonists
|
AU2958195A
(en)
|
1994-06-29 |
1996-01-25 |
Texas Biotechnology Corporation |
Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
|
US6248713B1
(en)
|
1995-07-11 |
2001-06-19 |
Biogen, Inc. |
Cell adhesion inhibitors
|
EP0845987A4
(de)
|
1995-08-08 |
2000-05-24 |
Fibrogen Inc |
C - proteinaseinhibitoren zur behandlung von störungen, die mit einer kollagenüberproduktion zusammenhängen
|
ES2271971T3
(es)
|
1996-07-25 |
2007-04-16 |
Biogen Idec Ma Inc. |
Inhibidores de la adhesion celular.
|
WO1998042656A1
(en)
|
1997-03-21 |
1998-10-01 |
Cytel Corporation |
Novel compounds
|
ES2257808T3
(es)
|
1997-05-29 |
2006-08-01 |
MERCK & CO., INC. (A NEW JERSEY CORP.) |
Acidos biarilalcanoicos como inhibidores de adhesion celular.
|
CA2291778A1
(en)
|
1997-05-29 |
1998-12-03 |
Merck & Co., Inc. |
Heterocyclic amide compounds as cell adhesion inhibitors
|
AU728435B2
(en)
|
1997-05-29 |
2001-01-11 |
Merck & Co., Inc. |
Sulfonamides as cell adhesion inhibitors
|
DE69818049T2
(de)
|
1997-06-23 |
2004-07-15 |
Tanabe Seiyaku Co., Ltd. |
Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
|
BR9811573A
(pt)
|
1997-07-31 |
2000-09-19 |
Elan Pharm Inc |
Compostos de benzila que inibem a adesão de leucócitos mediada por vla-4
|
KR20010022405A
(ko)
|
1997-07-31 |
2001-03-15 |
진 엠. 듀발 |
Vla-4에 의해 매개된 백혈구 유착을 억제하는설포닐화된 디펩타이드 화합물
|
DE69834642T2
(de)
|
1997-07-31 |
2007-05-03 |
Elan Pharmaceuticals, Inc., South San Francisco |
Verbindungen mit einer 4-amino-phenylalaningruppe, die die vla-4 vermittelte adhäsion von leukozyten inhibieren
|
WO1999006431A1
(en)
|
1997-07-31 |
1999-02-11 |
Elan Pharmaceuticals, Inc. |
Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
|
WO1999013898A1
(en)
|
1997-08-15 |
1999-03-25 |
Stefan Niewiarowski |
EC-3, AN INHIBITOR OF α4β1 AND α4β7 INTEGRINS
|
BR9811988A
(pt)
|
1997-08-22 |
2000-09-05 |
Hoffmann La Roche |
Derivados de n-alcanoilfenilalanina
|
CA2301377C
(en)
|
1997-08-22 |
2009-10-06 |
F. Hoffmann-La Roche Ag |
N-aroylphenylalanine derivatives
|
EP0970965A4
(de)
|
1997-11-13 |
2002-07-17 |
Toray Industries |
Zyklische peptide und medizinische verwendung davon
|
US6645939B1
(en)
|
1997-11-24 |
2003-11-11 |
Merck & Co., Inc. |
Substituted β-alanine derivatives as cell adhesion inhibitors
|
CA2309338A1
(en)
|
1997-11-24 |
1999-06-03 |
Merck & Co., Inc. |
Cyclic amino acid derivatives as cell adhesion inhibitors
|
AU751950B2
(en)
|
1997-11-24 |
2002-09-05 |
Merck & Co., Inc. |
Substituted beta-alanine derivatives as cell adhesion inhibitors
|
ATE299023T1
(de)
|
1997-12-17 |
2005-07-15 |
Merck & Co Inc |
Integrinrezeptor antagonisten
|
MY153569A
(en)
|
1998-01-20 |
2015-02-27 |
Mitsubishi Tanabe Pharma Corp |
Inhibitors of ?4 mediated cell adhesion
|
AU3748399A
(en)
|
1998-04-16 |
1999-11-01 |
Texas Biotechnology Corporation |
N,n-disubstituted amides that inhibit the binding of integrins to their receptors
|
CZ298413B6
(cs)
|
1998-05-28 |
2007-09-26 |
Biogen Idec Ma Inc. |
Beta-Alaninový derivát, farmaceutická kompozice tento derivát obsahující a použití tohoto derivátu pro prípravu léciva
|
GB9811969D0
(en)
|
1998-06-03 |
1998-07-29 |
Celltech Therapeutics Ltd |
Chemical compounds
|
AU8059598A
(en)
|
1998-06-11 |
1999-12-30 |
Merck & Co., Inc. |
Heterocyclic amide compounds as cell adhesion inhibitors
|
TW591026B
(en)
|
1998-06-23 |
2004-06-11 |
Upjohn Co |
Inhibitors of alpha4beta1 mediated cell adhesion
|
WO2000002903A1
(en)
|
1998-07-10 |
2000-01-20 |
Cytel Corporation |
Cs-1 peptidomimetics, compositions and methods of using the same
|
WO2000005223A2
(en)
|
1998-07-23 |
2000-02-03 |
Astrazeneca Ab |
Heterocyclic derivatives and their use as integrin inhibitors
|
KR20010085630A
(ko)
|
1998-08-26 |
2001-09-07 |
앤드류 앵뉴 |
세포 접착 억제를 조절하는 아자-비사이클
|
EP1140792A1
(de)
|
1998-12-14 |
2001-10-10 |
American Home Products Corporation |
3,4-diamino-3-cyclobutene-1,2-dione derivate welche leukocytenadhesion verursacht von vla-4 inhibieren
|
GB9828074D0
(en)
|
1998-12-18 |
1999-02-17 |
Glaxo Group Ltd |
Therapeutically useful compounds
|
US6545003B1
(en)
|
1999-01-22 |
2003-04-08 |
Elan Pharmaceuticals, Inc. |
Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
|
DE60021251D1
(de)
|
1999-01-22 |
2005-08-18 |
Elan Pharm Inc |
Multizyklische verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion
|
WO2000043369A1
(en)
|
1999-01-22 |
2000-07-27 |
Elan Pharmaceuticals, Inc. |
Compounds which inhibit leukocyte adhesion mediated by vla-4
|
WO2000043413A2
(en)
|
1999-01-26 |
2000-07-27 |
Elan Pharmaceuticals, Inc. |
Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
|
SI1154993T1
(en)
|
1999-02-18 |
2004-12-31 |
F. Hoffmann-La Roche Ag |
Thioamide derivatives
|
AU3246600A
(en)
|
1999-03-01 |
2000-09-21 |
Elan Pharmaceuticals, Inc. |
Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
|
US6265572B1
(en)
|
1999-04-20 |
2001-07-24 |
Hoffmann-La Roche Inc. |
Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents
|
GB9909409D0
(en)
|
1999-04-24 |
1999-06-23 |
Zeneca Ltd |
Chemical compounds
|
RU2263109C2
(ru)
|
1999-05-07 |
2005-10-27 |
Тексэс Байотекнолоджи Копэрейшн |
ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО
|
EP1189612A4
(de)
|
1999-06-30 |
2005-02-16 |
Daiichi Seiyaku Co |
Vla-4 hemmende verbindungen
|
JP3795305B2
(ja)
|
1999-07-19 |
2006-07-12 |
田辺製薬株式会社 |
医薬組成物
|
CN1376143A
(zh)
|
1999-07-26 |
2002-10-23 |
东丽株式会社 |
羧酸衍生物及以其作为有效成分的粘连分子抑制剂
|
EP1741428A3
(de)
|
1999-08-13 |
2007-05-09 |
Biogen Idec MA, Inc. |
Hemmer der Zelladhäsion
|
WO2001012183A1
(en)
|
1999-08-16 |
2001-02-22 |
Merck & Co., Inc. |
Heterocycle amides as cell adhesion inhibitors
|
AU6909300A
(en)
|
1999-08-20 |
2001-03-19 |
Merck & Co., Inc. |
Substituted ureas as cell adhesion inhibitors
|
CA2385882C
(en)
|
1999-09-24 |
2009-11-24 |
Genentech, Inc. |
Tyrosine derivatives
|
AU7961200A
(en)
|
1999-10-29 |
2001-05-14 |
Kaken Pharmaceutical Co., Ltd. |
Urea derivative, process for producing the same, and medicine containing the urea derivative
|
EP1233013B1
(de)
|
1999-11-18 |
2007-02-28 |
Ajinomoto Co., Inc. |
Phenylalaninderivate
|
BR0016172A
(pt)
|
1999-12-06 |
2002-08-20 |
|
4-piridinil-n-acil-l-fenilalaninas
|
SI1237878T1
(sl)
|
1999-12-06 |
2007-08-31 |
Hoffmann La Roche |
4-pirimidinil-n-acil-l-fenilanin
|
ES2415708T3
(es)
|
1999-12-16 |
2013-07-26 |
Biogen Idec Ma Inc. |
Métodos de tratamiento de la lesión isquémica o hemorrágica del sistema nervioso central mediante el uso de antagonistas anti-integrina alfa4
|
DE19962936A1
(de)
|
1999-12-24 |
2001-06-28 |
Bayer Ag |
Neue beta-Aminosäureverbindungen als Integrinantagonisten
|
JP4784803B2
(ja)
|
1999-12-28 |
2011-10-05 |
味の素株式会社 |
新規フェニルアラニン誘導体
|
GB0001348D0
(en)
|
2000-01-21 |
2000-03-08 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0001346D0
(en)
|
2000-01-21 |
2000-03-08 |
Astrazeneca Uk Ltd |
Chemical compounds
|
AU2882801A
(en)
|
2000-01-28 |
2001-08-07 |
Kaken Pharmaceutical Co., Ltd. |
Azepine derivatives
|
US20040018192A1
(en)
|
2000-02-03 |
2004-01-29 |
Toshiaki Wakabayashi |
Integrin expression inhibitors
|
WO2001056994A1
(en)
|
2000-02-04 |
2001-08-09 |
Biogen, Inc. |
Integrin antagonists
|
WO2001068586A2
(en)
|
2000-03-14 |
2001-09-20 |
Novartis Ag |
α4β1 AND α4β7 INTEGRIN INHIBITORS
|
WO2001070670A1
(fr)
|
2000-03-23 |
2001-09-27 |
Ajinomoto Co., Inc. |
Nouveau derive de phenylalanine
|
US6960597B2
(en)
|
2000-06-30 |
2005-11-01 |
Orth-Mcneil Pharmaceutical, Inc. |
Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
|
US6794506B2
(en)
|
2000-07-21 |
2004-09-21 |
Elan Pharmaceuticals, Inc. |
3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
|
PE20020384A1
(es)
|
2000-07-21 |
2002-05-28 |
Schering Corp |
PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C
|
AU2001278986A1
(en)
|
2000-07-21 |
2002-02-05 |
Elan Pharmaceuticals, Inc. |
3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors
|
US7335673B2
(en)
|
2000-08-11 |
2008-02-26 |
Kaken Pharmaceutical Co., Ltd. |
2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage
|
SI1288205T1
(sl)
|
2000-08-18 |
2011-05-31 |
Ajinomoto Kk |
Novi derivati fenilalanina
|
US20020035104A1
(en)
|
2000-08-18 |
2002-03-21 |
Genentech, Inc. |
Integrin receptor inhibitors
|
MY129000A
(en)
|
2000-08-31 |
2007-03-30 |
Tanabe Seiyaku Co |
INHIBITORS OF a4 MEDIATED CELL ADHESION
|
CA2422135A1
(en)
|
2000-09-14 |
2003-03-13 |
Toray Industries, Inc. |
Urea derivatives and adhesion molecule inhibitors containing the same as effective ingredients
|
CA2423007C
(en)
|
2000-09-25 |
2010-06-01 |
Toray Industries, Inc. |
Spiro derivatives and adhesion molecule inhibitors containing the same as effective ingredients
|
JP4895067B2
(ja)
|
2000-09-29 |
2012-03-14 |
味の素株式会社 |
新規フェニルアラニン誘導体
|
CA2430978C
(en)
|
2000-12-28 |
2012-05-15 |
Daiichi Pharmaceutical Co., Ltd. |
Vla-4 inhibitors
|
ES2200617B1
(es)
|
2001-01-19 |
2005-05-01 |
Almirall Prodesfarma, S.A. |
Derivados de urea como antagonistas de integrinas alfa 4.
|
JP4255285B2
(ja)
|
2001-02-21 |
2009-04-15 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
インテグリン発現抑制を介した血管新生抑制剤の効果を検定する方法
|
DE60218436T2
(de)
|
2001-02-22 |
2007-10-31 |
Celltech R&D Ltd., Slough |
Phenylalaninenamidderivate mit einer cyclobutengruppe zur verwendung als integrininhibitoren
|
ATE443736T1
(de)
|
2001-06-20 |
2009-10-15 |
Asahi Chemical Ind |
Thermoplastharzzusammensetzung
|
JP2005022976A
(ja)
|
2001-07-18 |
2005-01-27 |
Ajinomoto Co Inc |
カルボン酸誘導体
|
JP4164871B2
(ja)
|
2001-07-26 |
2008-10-15 |
味の素株式会社 |
新規フェニルプロピオン酸誘導体
|
US7557130B2
(en)
|
2001-07-26 |
2009-07-07 |
Ucb Pharma, S.A. |
Bicyclic heteroaromatic alanines
|
JP2003048889A
(ja)
|
2001-08-01 |
2003-02-21 |
Ajinomoto Co Inc |
新規核酸系化合物
|
WO2003016907A1
(fr)
|
2001-08-17 |
2003-02-27 |
Eisai Co. Ltd. |
Reactif de dosage pour antigene de la laminine 5 dans un echantillon biologique et procede de dosage
|
JPWO2003024933A1
(ja)
|
2001-09-12 |
2004-12-24 |
科研製薬株式会社 |
2−フェニル−3−ヘテロアリールプロピオン酸誘導体またはその塩、それを用いた医薬
|
GB0127423D0
(en)
|
2001-11-15 |
2002-01-09 |
Glaxo Group Ltd |
Process
|
WO2003053926A1
(fr)
|
2001-12-13 |
2003-07-03 |
Ajinomoto Co.,Inc. |
Nouveau derive de phenylalanine
|
WO2003070709A1
(fr)
|
2002-02-20 |
2003-08-28 |
Ajinomoto Co.,Inc. |
Nouveau derive de phenylalanine
|
JP4233353B2
(ja)
|
2002-02-27 |
2009-03-04 |
田辺三菱製薬株式会社 |
医薬組成物
|
MY140707A
(en)
|
2002-02-28 |
2010-01-15 |
Mitsubishi Tanabe Pharma Corp |
Process for preparing a phenylalanine derivative and intermediates thereof
|
JP2003277340A
(ja)
|
2002-03-22 |
2003-10-02 |
Toray Ind Inc |
接着分子阻害剤及び新規アミノ酸誘導体
|
US20060241132A1
(en)
|
2002-03-22 |
2006-10-26 |
Toray Industries, Inc. A Corporation Of Japan |
Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient
|
JPWO2003089410A1
(ja)
|
2002-04-19 |
2005-08-25 |
協和醗酵工業株式会社 |
フェニルアラニン誘導体
|
CN1649842A
(zh)
|
2002-04-30 |
2005-08-03 |
Ucb公司 |
2,6-喹啉基和2,6-萘基衍生物、用于制备它们的方法和它们作为vla-4抑制剂的用途
|
TWI281470B
(en)
|
2002-05-24 |
2007-05-21 |
Elan Pharm Inc |
Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
|
TW200307671A
(en)
|
2002-05-24 |
2003-12-16 |
Elan Pharm Inc |
Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
|
GB0216568D0
(en)
|
2002-07-17 |
2002-08-28 |
Celltech R&D Ltd |
Chemical compounds
|
GB0216574D0
(en)
|
2002-07-17 |
2002-08-28 |
Celltech R&D Ltd |
Chemical compounds
|
GB0216571D0
(en)
|
2002-07-17 |
2002-08-28 |
Celltech R&D Ltd |
Chemical compounds
|
WO2004014844A2
(en)
|
2002-08-09 |
2004-02-19 |
Transtech Pharma, Inc. |
Aryl and heteroaryl compounds and methods to modulate coagulation
|
GB0218630D0
(en)
|
2002-08-10 |
2002-09-18 |
Tanabe Seiyaku Co |
Novel compounds
|
KR101145252B1
(ko)
|
2003-01-08 |
2012-05-24 |
유니버시티 오브 워싱톤 |
항균제
|
US7576101B2
(en)
|
2003-01-24 |
2009-08-18 |
Elan Pharmaceuticals, Inc. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
CN101386600B
(zh)
|
2003-02-20 |
2011-07-06 |
味之素株式会社 |
具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体
|
JP2004277338A
(ja)
|
2003-03-14 |
2004-10-07 |
Nippon Soda Co Ltd |
N−アシルアミノ酸類の製造方法
|
ES2219177B1
(es)
|
2003-05-05 |
2006-02-16 |
Almirall Prodesfarma, S.A. |
Derivados de n-(2-feniletil) sulfamida como antagonistas de la integrina alfa4.
|
CA2525934A1
(en)
|
2003-05-20 |
2004-12-02 |
Genentech, Inc. |
Thiocarbamate inhibitors of alpha-4 integrins
|
PE20050232A1
(es)
|
2003-06-25 |
2005-04-01 |
Elan Pharm Inc |
Metodo y composiciones para tratar la artritis reumatoide
|
TWI340134B
(en)
|
2003-07-24 |
2011-04-11 |
Daiichi Seiyaku Co |
Cyclohexanecarboxylic acids
|
US7501538B2
(en)
|
2003-08-08 |
2009-03-10 |
Transtech Pharma, Inc. |
Aryl and heteroaryl compounds, compositions and methods of use
|
US20070099938A1
(en)
|
2003-10-24 |
2007-05-03 |
Ono Pharmaceutical Co., Ltd. |
Antistress drug and medical use thereof
|
US20050176755A1
(en)
|
2003-10-31 |
2005-08-11 |
Dyatkin Alexey B. |
Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
|
ES2383525T3
(es)
|
2003-11-05 |
2012-06-21 |
Sarcode Bioscience Inc. |
Moduladores de la adhesión celular
|
WO2005046697A1
(ja)
|
2003-11-14 |
2005-05-26 |
Ajinomoto Co., Inc. |
フェニルアラニン誘導体の徐放性経口投与製剤
|
CN100563658C
(zh)
|
2003-11-14 |
2009-12-02 |
味之素株式会社 |
苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
|
WO2005051925A1
(ja)
|
2003-11-27 |
2005-06-09 |
Ajinomoto Co., Inc. |
フェニルアラニン誘導体の結晶及びその製造方法
|
GB0329584D0
(en)
|
2003-12-20 |
2004-01-28 |
Tanabe Seiyaku Co |
Novel compounds
|
BRPI0418026A
(pt)
|
2003-12-22 |
2007-04-17 |
Ajinomoto Kk |
derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
|
MY140489A
(en)
|
2003-12-26 |
2009-12-31 |
Eisai R&D Man Co Ltd |
1,2-di (cyclic) substituted benzene compounds
|
US7595318B2
(en)
|
2004-01-23 |
2009-09-29 |
Elan Pharmaceuticals, Inc. |
Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
|
KR20070004676A
(ko)
|
2004-02-10 |
2007-01-09 |
얀센 파마슈티카 엔.브이. |
알파4 인테그린의 길항제로서의 피리다지논
|
US20050209232A1
(en)
|
2004-02-10 |
2005-09-22 |
Kent Barbay |
Pyridazinone ureas as antagonists of alpha4 integrins
|
WO2005087760A1
(en)
|
2004-03-10 |
2005-09-22 |
Merck & Co., Inc. |
Vla-4 antagonists
|
JP2007531735A
(ja)
|
2004-04-01 |
2007-11-08 |
エラン ファーマシューティカルズ,インコーポレイテッド |
ステロイド節約剤および該節約剤を使用する方法
|
JP2007532681A
(ja)
|
2004-04-16 |
2007-11-15 |
ジェネンテック・インコーポレーテッド |
B細胞の枯渇を増大させる方法
|
US7618981B2
(en)
|
2004-05-06 |
2009-11-17 |
Cytokinetics, Inc. |
Imidazopyridinyl-benzamide anti-cancer agents
|
TW200610754A
(en)
|
2004-06-14 |
2006-04-01 |
Daiichi Seiyaku Co |
Vla-4 inhibitor
|
MX2007000228A
(es)
|
2004-07-08 |
2007-03-30 |
Elan Pharm Inc |
Antagonistas de vla-4 multivalentes que comprenden porsiones de polietilenglicol.
|
US7196112B2
(en)
|
2004-07-16 |
2007-03-27 |
Biogen Idec Ma Inc. |
Cell adhesion inhibitors
|
EP1781686B1
(de)
|
2004-08-16 |
2009-05-06 |
Merck & Co., Inc. |
Vla-4-antagonisten
|
WO2006028393A1
(en)
|
2004-09-09 |
2006-03-16 |
Auckland Uniservices Limited |
Novel peptides and methods for the treatment of inflammatory disease
|
WO2006052962A2
(en)
|
2004-11-10 |
2006-05-18 |
Janssen Pharmaceutica, N.V. |
Bicyclic triazole a4 integrin inhibitors
|
KR101274879B1
(ko)
|
2004-12-20 |
2013-06-14 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
1-시클로프로필메틸-4-[2-(3,3,5,5-테트라메틸시클로헥실)페닐]피페라진의 염 및 결정
|
WO2006066780A1
(en)
|
2004-12-22 |
2006-06-29 |
F. Hoffmann-La Roche Ag |
Combinations of valategrast and montelukast for treating asthma
|
KR101250889B1
(ko)
|
2004-12-24 |
2013-04-04 |
도레이 카부시키가이샤 |
글리신 유도체 및 그 용도
|
WO2006081986A1
(en)
|
2005-02-07 |
2006-08-10 |
F.Hoffmann-La Roche Ag |
Bambuterol and integrin inhibitor combination
|
WO2006090234A1
(en)
|
2005-02-22 |
2006-08-31 |
Ranbaxy Laboratories Limited |
Heterocyclic derivatives as cell adhesion inhibitors
|
WO2006096807A1
(en)
|
2005-03-08 |
2006-09-14 |
Janssen Pharmaceutica N.V. |
Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists
|
CN101155798A
(zh)
|
2005-04-14 |
2008-04-02 |
默克公司 |
Vla-4拮抗剂
|
WO2006112738A1
(en)
|
2005-04-19 |
2006-10-26 |
Auckland Uniservices Limited |
Novel peptides and methods for the treatment of inflammatory disorders
|
US20090069376A1
(en)
|
2005-04-21 |
2009-03-12 |
Ping Liu |
VLA-4 Antagonists
|
NZ563577A
(en)
|
2005-05-20 |
2011-04-29 |
Elan Pharm Inc |
Imidazolone phenylalanine derivatives as VLA-4 antagonists
|
CA2609255A1
(en)
|
2005-05-25 |
2006-11-30 |
Eisai R&D Management Co., Ltd. |
Intermediate in production of [2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine compound
|
US20090163715A1
(en)
|
2005-05-25 |
2009-06-25 |
Eisai R&D Management Co., Ltd. |
Intermediate in Production of [2-(3,3,5,5-Tetramethylcyclohexyl)phenyl]Piperazine Compound
|
JP2008542407A
(ja)
|
2005-06-09 |
2008-11-27 |
ユセベ ファルマ ソシエテ アノニム |
2,6キノリニル誘導体、それらを調製するための方法及び薬剤としてのそれらの使用
|
EP2402326A1
(de)
|
2005-06-21 |
2012-01-04 |
Ajinomoto Co., Inc. |
Kristalle aus Hydrochloridsalzen von Phenylalaninderivaten, Herstellungsverfahren und Verwendung dafür
|
TW200726767A
(en)
|
2005-07-04 |
2007-07-16 |
Astrazeneca Ab |
Chemical compounds 2
|
EP1961750B1
(de)
|
2005-12-13 |
2013-09-18 |
Daiichi Sankyo Company, Limited |
Vla-4-hemmendes arzneimittel
|
EP1978928B1
(de)
|
2006-01-18 |
2010-03-31 |
F. Hoffmann-la Roche AG |
Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
|
CA2643838A1
(en)
|
2006-02-27 |
2007-09-07 |
Elan Pharmaceuticals, Inc. |
Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
|
WO2007100763A2
(en)
|
2006-02-28 |
2007-09-07 |
Elan Pharmaceuticals, Inc. |
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
|
EP2103601B1
(de)
|
2006-11-22 |
2012-03-14 |
Ajinomoto Co., Inc. |
Verfahren zur herstellung von phenylalaninderivaten mit chinazolindiongerüsten, und zwischenprodukte für die herstellung
|
WO2008064830A1
(en)
|
2006-11-27 |
2008-06-05 |
Ucb Pharma, S.A. |
Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses
|
MX2009009792A
(es)
|
2007-03-12 |
2009-09-23 |
Cytopia Res Pty Ltd |
Compuestos de fenil amino pirimidina y usos de los mismos.
|
WO2008125210A1
(en)
|
2007-04-12 |
2008-10-23 |
Ucb Pharma, S.A. |
Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases
|
WO2008138591A2
(en)
|
2007-05-14 |
2008-11-20 |
Ucb Pharma, S.A. |
Bicyclic and heterobicyclic derivatives,processes for preparing them and their uses
|
TWI519508B
(zh)
|
2007-06-12 |
2016-02-01 |
Achaogen Inc |
抗菌劑
|
JP2011506322A
(ja)
|
2007-12-07 |
2011-03-03 |
エラン ファーマシューティカルズ,インコーポレイテッド |
液性腫瘍を治療するための方法および組成物
|
WO2009124755A1
(en)
|
2008-04-08 |
2009-10-15 |
European Molecular Biology Laboratory (Embl) |
Compounds with novel medical uses and method of identifying such compounds
|
CA2724413C
(en)
|
2008-05-15 |
2016-10-18 |
Duke University |
Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
|
PT2310509E
(pt)
|
2008-07-21 |
2015-05-19 |
Apogenix Gmbh |
Moléculas de tnfsf em cadeia simples
|
KR20100101054A
(ko)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
|
WO2010105363A1
(en)
|
2009-03-16 |
2010-09-23 |
Andrei Yudin |
Cyclic amino acid molecules and methods of preparing the same
|
GB0905641D0
(en)
|
2009-04-01 |
2009-05-13 |
Serodus As |
Compounds
|
BRPI1015259A2
(pt)
|
2009-04-27 |
2016-05-03 |
Elan Pharm Inc |
antagonistas de piridinona de integrinas alfa-4
|
EA201290165A1
(ru)
|
2009-10-21 |
2012-11-30 |
Глаксо Груп Лимитед |
Способ получения производного фенилаланина
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
EP2993173A1
(de)
|
2010-03-29 |
2016-03-09 |
Ajinomoto Co., Inc. |
Kristalle von Salzen von Phenylalaninderivaten
|
EP2554169B1
(de)
|
2010-03-29 |
2019-11-20 |
EA Pharma Co., Ltd. |
Pharmazeutisches präparat mit einem phenylalaninderivat
|
EP2569331A1
(de)
|
2010-05-10 |
2013-03-20 |
Perseid Therapeutics LLC |
Polypeptid-inhibitoren von vla4
|
WO2011150499A1
(en)
|
2010-05-31 |
2011-12-08 |
The Governing Council Of The University Of Toronto |
A method to insert molecular fragments into cyclic molecules
|
WO2011159781A2
(en)
|
2010-06-17 |
2011-12-22 |
Senomyx, Inc. |
Bitter taste modulators
|
AU2011281132B2
(en)
|
2010-07-20 |
2014-01-30 |
Council Of Scientific & Industrial Research |
Pyridin- 2 - YL sulfanyl acid esters and process for the preparation thereof
|
CA2997474C
(en)
|
2010-11-16 |
2020-12-15 |
Texas Heart Institute |
Agonists that enhance binding of integrin-expressing cells to integrin receptors
|
AU2012212323A1
(en)
|
2011-02-01 |
2013-09-12 |
The Board Of Trustees Of The University Of Illinois |
HDAC inhibitors and therapeutic methods using the same
|
CA2854658A1
(en)
|
2011-11-09 |
2013-05-16 |
Aestus Therapeutics, Inc. |
Methods of treating schizophrenia with phenylalanine enamide derivative inhibitors of .alpha.4 integrin possessing a cyclobutene group
|
RU2014132564A
(ru)
|
2012-01-27 |
2016-03-20 |
Ф. Хоффманн-Ля Рош Аг |
Хитозан, ковалентно связанный с низкомолекулярным антагонистом интегрина, для нацеленной доставки
|
WO2013110680A1
(en)
|
2012-01-27 |
2013-08-01 |
F. Hoffmann-La Roche Ag |
Integrin antagonist conjugates for targeted delivery to cells expressing vla-4
|
US20130303763A1
(en)
|
2012-03-30 |
2013-11-14 |
Michael D. Gershon |
Methods and compositions for the treatment of necrotizing enterocolitis
|
WO2013161904A1
(ja)
|
2012-04-24 |
2013-10-31 |
味の素株式会社 |
スルホンアミド誘導体及びその医薬用途
|
US9013997B2
(en)
|
2012-06-01 |
2015-04-21 |
Broadcom Corporation |
System for performing distributed data cut-through
|
WO2014052605A1
(en)
|
2012-09-26 |
2014-04-03 |
Kflp Biotech, Llc |
Compounds for the treatment and prevention of retroviral infections
|
JPWO2014051056A1
(ja)
|
2012-09-28 |
2016-08-22 |
東レ株式会社 |
グリシン誘導体の結晶及びその医薬用途
|
US20150045435A1
(en)
|
2013-08-06 |
2015-02-12 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating diabetes
|
JP6399874B2
(ja)
|
2013-09-20 |
2018-10-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
化合物の抗炎症効果または免疫抑制効果を予測する方法
|
PT3064491T
(pt)
|
2013-10-29 |
2020-02-20 |
Ea Pharma Co Ltd |
Derivado de sulfonamida e sua utilização medicinal
|
JP6483148B2
(ja)
|
2014-03-14 |
2019-03-13 |
エアーピオ セラピューティクス インコーポレイテッド |
HPTP−β阻害剤
|
WO2015172196A1
(en)
|
2014-05-13 |
2015-11-19 |
Monash University |
Heterocyclic compounds and use of same
|
JP2016037468A
(ja)
|
2014-08-07 |
2016-03-22 |
味の素株式会社 |
スルホンアミド誘導体及びその医薬用途
|
JP2016037467A
(ja)
|
2014-08-07 |
2016-03-22 |
味の素株式会社 |
スルホンアミド誘導体及びその医薬用途
|
MX2017002985A
(es)
|
2014-09-10 |
2017-11-17 |
Epizyme Inc |
Inhibidores de smyd.
|
WO2016051828A1
(ja)
|
2014-09-29 |
2016-04-07 |
味の素株式会社 |
潰瘍性大腸炎の治療用医薬組成物
|
US10383842B2
(en)
|
2015-02-13 |
2019-08-20 |
Global Biolife Inc. |
Method and composition for preventing and treating viral infections
|
JP2018515424A
(ja)
|
2015-03-10 |
2018-06-14 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
抗アルファvベータ1インテグリン阻害剤及び使用方法
|
TN2017000538A1
(en)
|
2015-07-08 |
2019-04-12 |
Axerovision Inc |
Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
|
HUE061437T2
(hu)
|
2015-10-23 |
2023-06-28 |
Navitor Pharm Inc |
A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai
|
CN105483206B
(zh)
|
2016-01-06 |
2019-09-13 |
北京汉氏联合生物技术股份有限公司 |
一种用vcam-1检测msc促内皮细胞增殖能力的方法
|
JP6809713B2
(ja)
|
2016-01-20 |
2021-01-06 |
国立大学法人 岡山大学 |
炎症性腸疾患抑制剤
|
CN106995439B
(zh)
|
2016-01-26 |
2019-09-20 |
镇江圣安医药有限公司 |
氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途
|
WO2017132620A1
(en)
|
2016-01-29 |
2017-08-03 |
La Jolla Institute For Allergy And Immunology |
Methods and compositions using integrin-based therapeutics
|
WO2017135471A1
(ja)
|
2016-02-05 |
2017-08-10 |
Eaファーマ株式会社 |
α4β7インテグリン阻害剤
|
US10562898B2
(en)
|
2016-02-05 |
2020-02-18 |
Ea Pharma Co., Ltd. |
Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity
|
EP3509590A4
(de)
|
2016-09-07 |
2020-12-02 |
Pliant Therapeutics, Inc. |
N-acyl-aminosäure-verbindungen und verfahren zur verwendung
|
CA3038331A1
(en)
|
2016-09-28 |
2018-04-05 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
WO2018085574A2
(en)
|
2016-11-02 |
2018-05-11 |
Washington University |
Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
|
WO2018085552A1
(en)
|
2016-11-02 |
2018-05-11 |
Saint Louis University |
Integrin antagonists
|
DK3538525T3
(da)
|
2016-11-08 |
2022-08-29 |
Bristol Myers Squibb Co |
3-substituerede propionsyrer som alpha-v-integrinhæmmere
|
AR110139A1
(es)
|
2016-11-08 |
2019-02-27 |
Bristol Myers Squibb Co |
COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
|
CA3042693A1
(en)
|
2016-11-08 |
2018-05-17 |
Bristol-Myers Squibb Company |
Pyrrole amides as .alpha.v integrin inhibitors
|
MX2019005243A
(es)
|
2016-11-08 |
2019-08-05 |
Squibb Bristol Myers Co |
Derivados de indazol como antagonistas de integrina alfa v.
|
MA46746A
(fr)
|
2016-11-08 |
2019-09-18 |
Bristol Myers Squibb Co |
Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v
|
RU2769702C2
(ru)
|
2017-02-28 |
2022-04-05 |
Морфик Терапьютик, Инк. |
Ингибиторы интегрина avb6
|
MA47692A
(fr)
|
2017-02-28 |
2020-01-08 |
Morphic Therapeutic Inc |
Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
|
WO2018200625A1
(en)
|
2017-04-26 |
2018-11-01 |
Navitor Pharmaceuticals, Inc. |
Modulators of sestrin-gator2 interaction and uses thereof
|
US10246451B2
(en)
|
2017-04-26 |
2019-04-02 |
Aviara Pharmaceuticals, Inc. |
Propionic acid derivatives and methods of use thereof
|
US10875875B2
(en)
|
2017-04-26 |
2020-12-29 |
Aviara Pharmaceuticals, Inc. |
Propionic acid derivatives and methods of use thereof
|
JP2019031449A
(ja)
|
2017-08-04 |
2019-02-28 |
Eaファーマ株式会社 |
スルホンアミド誘導体及びそれを含有する医薬組成物
|
CN109721605B
(zh)
|
2017-10-31 |
2022-03-11 |
维眸生物科技(上海)有限公司 |
一种免疫细胞迁徙抑制剂
|
MX2020004455A
(es)
|
2017-11-07 |
2020-07-24 |
Bristol Myers Squibb Co |
Derivados de pirrolopirazina como inhibidores de integrina alfa v.
|
BR112020018064A2
(pt)
|
2018-03-07 |
2020-12-22 |
Pliant Therapeutics, Inc. |
Compostos de aminoácidos e métodos de uso
|
CA3092345A1
(en)
|
2018-03-13 |
2019-09-19 |
The Regents Of The University Of California |
Inhibitors of integrin alpha 2 beta 1 and methods of use
|
WO2019200202A1
(en)
|
2018-04-12 |
2019-10-17 |
Morphic Therapeutic, Inc. |
Antagonists of human integrin (alpha4)(beta7)
|
WO2020033724A1
(en)
|
2018-08-08 |
2020-02-13 |
The General Hospital Corporation |
Integrin antagonists
|
BR112021002839A2
(pt)
|
2018-08-17 |
2021-05-11 |
Oxurion NV |
antagonistas de integrina
|
EP3843727A4
(de)
|
2018-08-29 |
2022-08-17 |
Morphic Therapeutic, Inc. |
Inhibitoren von (alpha-v)(beta-6)-integrin
|
MX2021002181A
(es)
|
2018-08-29 |
2021-07-15 |
Morphic Therapeutic Inc |
Inhibicion de la integrina alfa v beta 6.
|
EP3843728A4
(de)
|
2018-08-29 |
2022-05-25 |
Morphic Therapeutic, Inc. |
Inhibitoren von (alpha-v)(beta-6)-integrin
|
CA3114240C
(en)
|
2018-10-30 |
2023-09-05 |
Gilead Sciences, Inc. |
Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
|
WO2020092375A1
(en)
|
2018-10-30 |
2020-05-07 |
Gilead Sciences, Inc. |
Quinoline derivatives as alpha4beta7 integrin inhibitors
|
CA3115820A1
(en)
|
2018-10-30 |
2020-05-07 |
Gilead Sciences, Inc. |
Compounds for inhibition of .alpha.4.beta.7 integrin
|
CN112969504B
(zh)
|
2018-10-30 |
2024-04-09 |
吉利德科学公司 |
用于抑制α4β7整合素的化合物
|
CA3148613A1
(en)
|
2019-08-14 |
2021-02-18 |
Gilead Sciences, Inc. |
Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin
|